142
Participants
Start Date
February 22, 2024
Primary Completion Date
January 12, 2026
Study Completion Date
August 27, 2027
Durvalumab
Participants that go on to receive surgery, will receive durvalumab for up to four cycles prior to surgery. Participants that go on to receive CRT will receive durvalumab for up to two cycles prior to CRT. All participants will receive durvalumab every four weeks until disease progression or recurrence or up to 12 months following surgery/CRT, unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
Research Site, Budapest
Research Site, Vienna
Research Site, Vienna
Research Site, Törökbálint
Research Site, The Bronx
Research Site, Prague
Research Site, Marseille
Research Site, Berlin
Research Site, Milan
Research Site, Milan
Research Site, Milan
Research Site, Charlottesville
Research Site, Großhansdorf
Research Site, Pavia
Research Site, Madrid
Research Site, Madrid
Research Site, Madrid
Research Site, Pamplona
Research Site, Toulouse
Research Site, Pessac
Research Site, Montpellier
Research Site, Peschiera del Garda
Research Site, La Tronche
Research Site, Bologna
Research Site, Valencia
Research Site, Moers
Research Site, Barakaldo
Research Site, Zaragoza
Research Site, Cologne
Research Site, Mulhouse
Research Site, Bari
Research Site, Paris
Research Site, Houston
Research Site, Olomouc
Research Site, Napoli
Research Site, Poitiers
Research Site, Palermo
Research Site, Würzburg
Research Site, Kingston
Research Site, Chicoutimi
Research Site, Montreal
Research Site, Brno
Research Site, Prague
Research Site, Lisbon
Research Site, Lisbon
Research Site, Barcelona
Research Site, L'Hospitalet de Llobregat
Research Site, Solna
Research Site, Uppsala
Lead Sponsor
AstraZeneca
INDUSTRY